Evidence map›Paper›PMID 30499073›Full record

ReviewInternal and emergency medicine2019

Vascular Behçet's syndrome: an update.

Giacomo Emmi, Alessandra Bettiol, Elena Silvestri, Gerardo Di Scala, Matteo Becatti, Claudia Fiorillo, Domenico Prisco

Abstract readReview
PubMed Publisher
In one paragraph

Review in Internal and emergency medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 3 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. SerumInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. THBS1BMC medicine · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Giacomo Emmi *Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy. giacomaci@yahoo.it.ORCID http://orcid.org/0000-0001-9575-8321
Alessandra Bettiol *Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
Elena SilvestriDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
Gerardo Di ScalaDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
Matteo BecattiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, Firenze, Italy.
Claudia FiorilloDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, Firenze, Italy.
Domenico PriscoDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet's syndrome (BS) is a complex vasculitis, characterised by peculiar histological, pathogenetic and clinical features. Superficial venous thrombosis (SVT) and deep vein thrombosis (DVT) are the most frequent vascular involvements, affecting altogether 15-40% of BS patients. Atypical thrombosis is also an important clinical feature of BS, involving the vascular districts of the inferior and superior vena cava, suprahepatic veins with Budd-Chiari syndrome, portal vein, cerebral sinuses and right ventricle. On the other hand, arterial involvement, although affecting only 3-5% of patients, represents a unique feature of BS, with aneurysms potentially affecting peripheral, visceral and pulmonary arteries. Vascular events in BS are promoted by inflammation, with neutrophils playing a key role in the pathogenesis of thrombotic events; in turn, coagulative components such as fibrinogen, thrombin, factor Xa and factor VIIa amplify the inflammatory cascade. Understanding the contribution of inflammatory and coagulation components in the pathogenesis of BS vascular events is crucial to define the most effective therapeutic strategy. Control of vascular thrombosis is achieved with immunosuppressants drugs rather than anticoagulants. In particular, use of azathioprine and cyclosporine in association with low-dose corticosteroids should be considered in DVT and SVT cases, while treatment with cyclophosphamide together with anti-TNF-α agents can be effectively used in arterial involvement. More recently, the anti-TNF-α drugs have also been reported as a valid alternative for the treatment also of venous events, especially DVT. An exception to the use of anticoagulant in BS could be represented by cerebral veins thrombosis. In this review, we will depict the main characteristics of the vascular involvement in BS, briefly describing histological and pathogenetic features, while focusing on the clinical and therapeutical approaches of the vascular manifestations of BS.

Indexed as

AzathioprineBehcet SyndromeCyclophosphamideCyclosporinsHumansImmunosuppressive AgentsTumor Necrosis Factor-alphaVena Cava, SuperiorVenous ThrombosisAzathioprineCyclophosphamideCyclosporinsImmunosuppressive AgentsTumor Necrosis Factor-alphaAdalimumabAngio-BehçetAnti-TNFαBehçet’s syndromeThrombosisVascular Behçet

Identifiers

PMID30499073
OpenAlexW2902345401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.